感染症分子検査市場 – 2029年までの世界予測

Report Overview

The molecular infectious disease testing market is projected to reach USD 17.78 billion in 2029 from an estimated value of USD 9.37 billion in 2024 at a CAGR of 13.7% during the forecast period.

感染症分子検査市場は、予測期間中のCAGR 13.7%で、2024年の推定93億7,000万米ドルから2029年には177億8,000万米ドルに達すると予測されています。

Rapid advancements in molecular diagnostic technologies are the main driving force in the molecular infectious disease testing market. Advancements in PCR, next-generation sequencing, and other technologies enhance test accuracy, speed of completion, and efficiency, making them more accessible at lower costs. Moreover, market players continue to develop high- end automated diagnostic platforms which further improves the workflow and increases diagnostic capabilities. This leads to accurate and timely diagnosis of infectious diseases, improved patient results, and improved surveillance of newly emerging pathogens. Through this, providers can make timely decisions, increasing the adoption rate of molecular diagnostics for infectious disease testing.

“Laboratory tests segment is expected to witness the fastest growth rate in the molecular infectious disease testing market, by test type, during the forecast period.”

Based on test type, the molecular infectious disease testing market can be divided into laboratory tests and point of care tests. Laboratory tests are the fastest-growing segment by test type in the molecular infectious disease testing market because of their high accuracy, scalability, and ability to handle all types of pathogens. These tests, including PCR and sequencing-based diagnostics, are widely used in hospitals and diagnostic laboratories for their precision in discovering infections. With the advances in laboratory automation and high-throughput technologies, turnaround times have decreased significantly, thereby making the laboratory-based molecular tests very efficient. Moreover, the need for extensive diagnostic panels that allow detection of multiple infections in one test further enhances the preference for laboratory-based solutions. With high reliability and the capability to address complex diagnostic needs, laboratory tests are the preferred solution for healthcare providers.

“Multiplex testing segment accounted for the largest market share in the molecular infectious disease testing market, by type, in 2023.”

Based on type, the molecular infectious disease testing market is bifurcated into singleplex testing and multiplex testing. The multiplex testing segment leads the molecular infectious disease testing market due to the capability of its ability to perform multiple tests for detecting and differentiating several pathogens in a single test. This efficiency cuts down time, costs, and resources for diagnosis, thus becoming one of the most preferred options by healthcare providers. All these factors together with the rise in co-infections, necessity for thorough diagnosis solutions, and demand for timely and accurate results have increased the multiplex testing market. In addition, new technology improvements include greater assay sensitivity and the introduction of user-friendly platforms that support widespread use of multiplex testing in hospitals and diagnostic labs.

“Asia Pacific: The fastest-growing market for molecular infectious disease testing”

The worldwide market for molecular infectious disease testing is categorized into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. The Asia Pacific region is experiencing significant growth in the molecular infectious disease testing market driven by the growing incidence of infectious diseases in the densely populated countries, together with growing awareness of the early detection of diseases, which has created a demand for more advanced diagnostics. Governments and healthcare organizations throughout the region are investing heavily to improve healthcare infrastructure, expand diagnostic capabilities, and support research initiatives. Moreover, growing emphasis on diseases surveillance and outbreak management and rising healthcare spending position Asia Pacific as one of the big contributors to growth in the entire market.

The break-up of the profile of primary participants in the molecular infectious disease testing market:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa- 4%

The key players in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Bruker (US), Seegene Inc. (South Korea), Genetic Signatures (Australia), Co-Diagnostics, Inc. (US), Savyon Diagnostics (Israel), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), Uniogen OY (Finland), geneOmbio Technologies (India), Advanced Molecular Diagnostics  (UK), GeneFirst Limited (UK), and altona Diagnostics GmbH (Germany).

Research Coverage:

This research report categorizes the molecular infectious disease testing market by product & service (reagents & kits, instruments, and services & software), by type (singleplex testing and multiplex testing), by test type (laboratory tests and point of car tests), by disease (respiratory infectious diseases (influenza, tuberculosis, pharyngitis, and other respiratory infectious diseases), gastrointestinal infectious diseases (hepatitis and other gastrointestinal infectious diseases), sexually transmitted diseases (human immunodeficiency virus, chlamydia trachomatis, neisseria gonorrhoea, syphilis, human papillomavirus, and other sexually transmitted diseases), vaginitis, meningitis, vector borne diseases, hospital-acquired infections, and other infectious diseases), by technology (polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, DNA sequencing & next generation sequencing, DNA microarrays, and other technologies), by end user (diagnostic laboratories, hospitals & clinics, and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the molecular infectious disease testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the molecular infectious disease testing market. Competitive analysis of upcoming startups in the molecular infectious disease testing market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular infectious disease testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Rising burden of infectious diseases, rapid technological advancements in molecular diagnostics, growing funding for molecular testing), opportunities (High growth opportunities in emerging economies), restraints (Inconsistent reimbursement policies), and challenges (Changing regulatory landscape, operational barriers and labor shortage) influencing the growth of the molecular infectious disease testing market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular infectious disease testing market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the molecular infectious disease testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular infectious disease testing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), and Abbott (US).

Table of Contents

1               INTRODUCTION              38

1.1           STUDY OBJECTIVES       38

1.2           MARKET DEFINITION   38

1.3           STUDY SCOPE   39

1.3.1        MARKET SEGMENTATION AND REGIONS COVERED                 39

1.3.2        INCLUSIONS AND EXCLUSIONS 40

1.3.3        YEARS CONSIDERED      40

1.4           CURRENCY CONSIDERED            41

1.5           STAKEHOLDERS               41

2               RESEARCH METHODOLOGY       42

2.1           RESEARCH DATA              42

2.2           RESEARCH APPROACH  42

2.2.1        SECONDARY RESEARCH                42

2.2.1.1    Key secondary sources         43

2.2.1.2    Key data from secondary sources       43

2.2.1.3    Objectives of secondary research       43

2.2.2        PRIMARY RESEARCH       44

2.2.2.1    Key primary sources             44

2.2.2.2    Key data from primary sources           45

2.2.2.3    Objectives of primary research           46

2.2.2.4    Key industry insights           47

2.2.2.5    Breakdown of primary interviews      47

2.3           MARKET SIZE ESTIMATION         48

2.3.1        BOTTOM-UP APPROACH              49

2.3.1.1    Company revenue estimation approach            49

2.3.1.2    Presentations of companies and primary interviews       49

2.3.1.3    Estimation of total molecular-based tests for HIV in US                 50

2.3.1.4    Growth forecast model        50

2.3.1.5    CAGR projections                 51

2.3.2        TOP-DOWN APPROACH                51

2.4           DATA TRIANGULATION                52

2.5           MARKET SHARE ANALYSIS           53

2.6           RESEARCH ASSUMPTIONS           54

2.6.1        PARAMETRIC ASSUMPTIONS     54

2.6.2        GROWTH RATE ASSUMPTIONS 54

2.7           RESEARCH LIMITATIONS             55

2.8           RISK ANALYSIS  55

3               EXECUTIVE SUMMARY  56

4               PREMIUM INSIGHTS       62

4.1           MOLECULAR INFECTIOUS DISEASE TESTING MARKET OVERVIEW          62

4.2           MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2024 VS. 2029   62

4.3           MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024 VS. 2029   63

4.4           MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024 VS. 2029        63

4.5           MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024 VS. 2029              64

4.6           MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY,

2024 VS. 2029       64

4.7           MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024 VS. 2029          65

4.8           MOLECULAR INFECTIOUS DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES            65

5               MARKET OVERVIEW       66

5.1           INTRODUCTION              66

5.2           MARKET DYNAMICS       66

5.2.1        DRIVERS               67

5.2.1.1    Rising burden of infectious diseases 67

5.2.1.2    Rapid technological advancements in molecular diagnostics                 68

5.2.1.3    Growing funding for molecular testing             69

5.2.2        RESTRAINTS      70

5.2.2.1    Inconsistent reimbursement policies 70

5.2.3        OPPORTUNITIES              70

5.2.3.1    High growth opportunities in emerging economies        70

5.2.4        CHALLENGES    71

5.2.4.1    Changing regulatory landscape          71

5.2.4.2    Operational barriers and labor shortage issues                72

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            72

5.4           PRICING ANALYSIS          73

5.4.1        INDICATIVE SELLING PRICE TREND, BY PRODUCT                 73

5.4.2        INDICATIVE SELLING PRICE TREND OF SEXUALLY TRANSMITTED DISEASE TESTS, BY KEY PLAYER                73

5.4.3        INDICATIVE SELLING PRICE TREND OF GASTROINTESTINAL DISEASE TESTS, BY KEY PLAYER    74

5.4.4        INDICATIVE SELLING PRICE TREND, BY REGION                 74

5.5           VALUE CHAIN ANALYSIS               75

5.6           SUPPLY CHAIN ANALYSIS             77

5.7           ECOSYSTEM ANALYSIS  78

5.8           INVESTMENT AND FUNDING SCENARIO               79

5.9           TECHNOLOGY ANALYSIS             80

5.9.1        KEY TECHNOLOGIES     80

5.9.1.1    Polymerase chain reaction  80

5.9.2        COMPLEMENTARY TECHNOLOGIES       81

5.9.2.1    Isolated nucleic acid amplification technology 81

5.9.3        ADJACENT TECHNOLOGIES       81

5.9.3.1    Next-generation sequencing               81

5.10         PATENT ANALYSIS          82

5.11         TRADE ANALYSIS             84

5.11.1      IMPORT DATA FOR HS CODE 3822            84

5.11.2      EXPORT DATA FOR HS CODE 3822            85

5.12         KEY CONFERENCES AND EVENTS, 2025–2026        85

5.13         CASE STUDY ANALYSIS 86

5.13.1      CASE STUDY 1: IMPROVED PATHOGEN-DIRECTED TREATMENT THROUGH RAPID SYNDROMIC PCR TESTING                 86

5.13.2      CASE STUDY 2: CLINICAL IMPACT OF MULTIPLEX MOLECULAR DIAGNOSTIC TESTING IN CHILDREN WITH ACUTE GASTROENTERITIS         87

5.13.3      CASE STUDY 3: IMPACT OF MOLECULAR POINT OF CARE TESTING FOR

GROUP A STREPTOCOCCUS PHARYNGITIS          87

5.14         REGULATORY LANDSCAPE         88

5.14.1      REGULATORY ANALYSIS               88

5.14.1.1  NORTH AMERICA             88

5.14.1.1.1                US           88

5.14.1.1.2                Canada   88

5.14.1.2  EUROPE               88

5.14.1.2.1                Germany                 89

5.14.1.2.2                UK          90

5.14.1.2.3                France    90

5.14.1.2.4                Italy         90

5.14.1.3  ASIA PACIFIC     91

5.14.1.3.1                China      91

5.14.1.3.2                Japan      91

5.14.1.3.3                India       91

5.14.1.3.4                Australia 92

5.14.1.4  LATIN AMERICA                92

5.14.1.4.1                Brazil      93

5.14.1.4.2                Mexico   93

5.14.1.5  MIDDLE EAST   93

5.14.1.5.1                Africa      93

5.14.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             94

5.15         PORTER’S FIVE FORCES ANALYSIS           95

5.15.1      BARGAINING POWER OF SUPPLIERS       97

5.15.2      BARGAINING POWER OF BUYERS             97

5.15.3      THREAT OF NEW ENTRANTS      97

5.15.4      THREAT OF SUBSTITUTES          97

5.15.5      INTENSITY OF COMPETITIVE RIVALRY 97

5.16         KEY STAKEHOLDERS AND BUYING CRITERIA     98

5.16.1      KEY STAKEHOLDERS IN BUYING PROCESS           98

5.16.2      BUYING CRITERIA           99

5.17         IMPACT OF AI ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET           99

5.17.1      INTRODUCTION              99

5.17.2      MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE

TESTING APPLICATIONS              100

5.17.3      AI USE CASES     101

5.17.4      KEY COMPANIES IMPLEMENTING AI      102

5.17.5      FUTURE OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET           102

6               MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE               103

6.1           INTRODUCTION              104

6.2           REAGENTS & KITS            104

6.2.1        ONGOING INNOVATIONS IN MOLECULAR DIAGNOSTICS TO SPUR GROWTH            104

6.3           INSTRUMENTS 108

6.3.1        RISING PREVALENCE OF INFECTIOUS DISEASES TO FOSTER GROWTH            108

6.4           SERVICES & SOFTWARE 112

6.4.1        INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO FACILITATE GROWTH            112

7               MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE               116

7.1           INTRODUCTION              117

7.2           MULTIPLEX TESTING    117

7.2.1        RISING DEMAND FOR FASTER DIAGNOSIS TO PROMOTE GROWTH      117

7.3           SINGLEPLEX TESTING   121

7.3.1        NEED FOR AFFORDABLE AND USER-FRIENDLY TESTING TO AUGMENT GROWTH               121

8               MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE   125

8.1           INTRODUCTION              126

8.2           LABORATORY TESTS     126

8.2.1        INCREASING NEED FOR AUTOMATION TO FAVOR GROWTH             126

8.3           POINT OF CARE TESTS  130

8.3.1        GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET 130

9               MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE        134

9.1           INTRODUCTION              135

9.2           RESPIRATORY INFECTIOUS DISEASES   136

9.2.1        INFLUENZA        139

9.2.1.1    Growing focus on faster diagnosis and control to propel market                 139

9.2.2        TUBERCULOSIS                142

9.2.2.1    Rise in undiagnosed and untreated cases to promote growth                 142

9.2.3        PHARYNGITIS   145

9.2.3.1    Need to differentiate between bacterial and viral infections to fuel growth    145

9.2.4        OTHER RESPIRATORY INFECTIOUS DISEASES    148

9.3           GASTROINTESTINAL INFECTIOUS DISEASES      150

9.3.1        HEPATITIS          153

9.3.1.1    Rising government initiatives to expedite growth           153

9.3.2        OTHER GASTROINTESTINAL INFECTIOUS DISEASES                 156

9.4           SEXUALLY TRANSMITTED DISEASES      159

9.4.1        HUMAN IMMUNODEFICIENCY VIRUS     162

9.4.1.1    Increasing number of blood transfusions and blood donations to augment growth    162

9.4.2        HUMAN PAPILLOMAVIRUS          166

9.4.2.1    Technological advancements for preventing human papillomavirus infections to drive market         166

9.4.3        CHLAMYDIA TRACHOMATIS      169

9.4.3.1    Increasing development of molecular tests to aid growth                 169

9.4.4        NEISSERIA GONORRHOEAE         172

9.4.4.1    Increasing development of novel assays to boost market                 172

9.4.5        SYPHILIS              174

9.4.5.1    Growing demand for affordable and rapid molecular diagnostic solutions to drive market     174

9.4.6        OTHER SEXUALLY TRANSMITTED DISEASES      177

9.5           HOSPITAL-ACQUIRED INFECTIONS        180

9.5.1        GROWING BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TO FUEL MARKET 180

9.6           VAGINITIS           183

9.6.1        INCREASING AWARENESS ABOUT WOMEN’S HEALTH TO BOLSTER GROWTH 183

9.7           MENINGITIS      186

9.7.1        RISING INCIDENCE OF INVASIVE MENINGOCOCCAL DISEASE TO ASSIST GROWTH    186

9.8           VECTOR-BORNE DISEASES          188

9.8.1        GROWING FOCUS ON DISEASE SURVEILLANCE TO PROPEL MARKET             188

9.9           OTHER INFECTIOUS DISEASES 191

10            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY            195

10.1         INTRODUCTION              196

10.2         POLYMERASE CHAIN REACTION               197

10.2.1      NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH             197

10.3         ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY  201

10.3.1      EMERGENCE OF NEW PATHOGENS TO STIMULATE GROWTH             201

10.4         DNA SEQUENCING & NEXT-GENERATION SEQUENCING                 204

10.4.1      GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL,

AND PARASITIC INFECTIONS TO DRIVE MARKET             204

10.5         IN SITU HYBRIDIZATION              207

10.5.1      NEED FOR SAFER AND MORE PRACTICAL TESTING IN CLINICAL SETTINGS TO FUEL MARKET 207

10.6         DNA MICROARRAYS        210

10.6.1      NEED FOR AFFORDABLE AND SENSITIVE DETECTION TO

ENCOURAGE GROWTH 210

10.7         OTHER TECHNOLOGIES               212

11            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER     215

11.1         INTRODUCTION              216

11.2         DIAGNOSTIC LABORATORIES    216

11.2.1      GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED

TESTING PROTOCOLS TO BOOST MARKET         216

11.3         HOSPITALS & CLINICS   219

11.3.1      RISING PATIENT VOLUME TO CONTRIBUTE TO GROWTH             219

11.4         OTHER END USERS         222

12            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION         225

12.1         INTRODUCTION              226

12.2         NORTH AMERICA             226

12.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 233

12.2.2      US           233

12.2.2.1  Presence of advanced healthcare infrastructure to augment growth    233

12.2.3      CANADA               238

12.2.3.1  Favorable government initiatives to fuel market              238

12.3         EUROPE               243

12.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      248

12.3.2      GERMANY           248

12.3.2.1  Increasing healthcare expenditure to advance growth    248

12.3.3      UK          253

12.3.3.1  Growing number of diagnostic centers to fuel market   253

12.3.4      FRANCE                258

12.3.4.1  Increasing demand for early disease diagnosis to augment growth                 258

12.3.5      ITALY    263

12.3.5.1  Growing adoption of advanced diagnostic technologies to

fuel market             263

12.3.6      RUSSIA 267

12.3.6.1  Increasing access to quality healthcare to facilitate growth                 267

12.3.7      SPAIN    272

12.3.7.1  Growing public health initiatives to boost market           272

12.3.8      REST OF EUROPE             276

12.4         ASIA PACIFIC     281

12.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 287

12.4.2      CHINA  288

12.4.2.1  Rising public access to modern healthcare to spur growth                 288

12.4.3      JAPAN   293

12.4.3.1  Universal healthcare reimbursement policy to foster growth                 293

12.4.4      INDIA    297

12.4.4.1  Increased private and public investments to bolster growth                 297

12.4.5      AUSTRALIA         303

12.4.5.1  Growing investments for testing centers and treatment

facilities to drive market      303

12.4.6      REST OF ASIA PACIFIC   308

12.5         LATIN AMERICA                313

12.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 318

12.5.2      BRAZIL 318

12.5.2.1  Growing focus on improving healthcare infrastructure to fuel market    318

12.5.3      MEXICO                323

12.5.3.1  Increasing accessibility and affordability of healthcare

services to foster growth      323

12.5.4      REST OF LATIN AMERICA             328

12.6         MIDDLE EAST & AFRICA                332

12.6.1      BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH             332

12.6.2      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 337

12.7         GCC COUNTRIES              337

12.7.1      GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET               337

12.7.2      MACROECONOMIC OUTLOOK FOR GCC COUNTRIES                 341

13            COMPETITIVE LANDSCAPE         342

13.1         INTRODUCTION              342

13.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            342

13.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET  342

13.3         REVENUE ANALYSIS, 2021–2023  344

13.4         MARKET SHARE ANALYSIS, 2023                 345

13.5         MARKET SHARE ANALYSIS OF EMEA REGION, 2023                 347

13.6         COMPANY VALUATION AND FINANCIAL METRICS                 347

13.7         BRAND/PRODUCT COMPARISON             348

13.8         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 349

13.8.1      STARS   349

13.8.2      EMERGING LEADERS     349

13.8.3      PERVASIVE PLAYERS      349

13.8.4      PARTICIPANTS 349

13.8.5      COMPANY FOOTPRINT, KEY PLAYERS, 2023         351

13.8.5.1  Company footprint               351

13.8.5.2  Region footprint   352

13.8.5.3  Product & service footprint 353

13.8.5.4  Test type footprint                354

13.8.5.5  Disease footprint  355

13.9         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023        356

13.9.1      PROGRESSIVE COMPANIES         356

13.9.2      RESPONSIVE COMPANIES            356

13.9.3      DYNAMIC COMPANIES  356

13.9.4      STARTING BLOCKS         356

13.9.5      COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2023        358

13.9.5.1  Detailed list of key startups/SMEs    358

13.9.5.2  Competitive benchmarking of startups/SMEs 358

13.10       COMPETITIVE SCENARIO             359

13.10.1   PRODUCT LAUNCHES AND APPROVALS               359

13.10.2   DEALS  360

14            COMPANY PROFILES      362

14.1         KEY PLAYERS     362

14.1.1      DANAHER            362

14.1.1.1  Business overview 362

14.1.1.2  Products offered   363

14.1.1.3  Recent developments           365

14.1.1.3.1                Product launches and approvals         365

14.1.1.3.2                Deals      366

14.1.1.3.3                Expansions             366

14.1.1.4  MnM view              367

14.1.1.4.1                Right to win           367

14.1.1.4.2                Strategic choices   367

14.1.1.4.3                Weaknesses and competitive threats 367

14.1.2      F. HOFFMANN-LA ROCHE LTD  368

14.1.2.1  Business overview 368

14.1.2.2  Products offered   369

14.1.2.3  Recent developments           371

14.1.2.3.1                Product launches and approvals         371

14.1.2.3.2                Deals      372

14.1.2.3.3                Expansions             373

14.1.2.4  MnM view              373

14.1.2.4.1                Right to win           373

14.1.2.4.2                Strategic choices   373

14.1.2.4.3                Weaknesses and competitive threats 373

14.1.3      BIOMÉRIEUX     374

14.1.3.1  Business overview 374

14.1.3.2  Products offered   375

14.1.3.3  Recent developments           377

14.1.3.3.1                Product launches and approvals         377

14.1.3.3.2                Deals      378

14.1.3.4  MnM view              378

14.1.3.4.1                Right to win           378

14.1.3.4.2                Strategic choices   379

14.1.3.4.3                Weaknesses and competitive threats 379

14.1.4      HOLOGIC, INC. 380

14.1.4.1  Business overview 380

14.1.4.2  Products offered   381

14.1.4.3  Recent developments           382

14.1.4.3.1                Product launches and approvals         382

14.1.4.3.2                Deals      383

14.1.4.4  MnM view              383

14.1.4.4.1                Right to win           383

14.1.4.4.2                Strategic choices   384

14.1.4.4.3                Weaknesses and competitive threats 384

14.1.5      ABBOTT               385

14.1.5.1  Business overview 385

14.1.5.2  Products offered   386

14.1.5.3  Recent developments           388

14.1.5.3.1                Product launches and approvals         388

14.1.5.3.2                Deals      388

14.1.5.4  MnM view              389

14.1.5.4.1                Right to win           389

14.1.5.4.2                Strategic choices   389

14.1.5.4.3                Weaknesses and competitive threats 389

14.1.6      THERMO FISHER SCIENTIFIC INC.            390

14.1.6.1  Business overview 390

14.1.6.2  Products offered   391

14.1.6.3  Recent developments           392

14.1.6.3.1                Product launches and approvals         392

14.1.6.3.2                Deals      393

14.1.7      QIAGEN                394

14.1.7.1  Business overview 394

14.1.7.2  Products offered   395

14.1.7.3  Recent developments           396

14.1.7.3.1                Product launches and approvals         396

14.1.7.3.2                Deals      398

14.1.7.3.3                Expansions             398

14.1.8      REVVITY               399

14.1.8.1  Business overview 399

14.1.8.2  Products offered   401

14.1.9      GRIFOLS, S.A.     402

14.1.9.1  Business overview 402

14.1.9.2  Products offered   403

14.1.9.3  Recent developments           404

14.1.9.3.1                Product launches and approvals         404

14.1.9.3.2                Deals      404

14.1.10   SEEGENE INC.   405

14.1.10.1                 Business overview 405

14.1.10.2                 Products offered   406

14.1.10.3                 Recent developments           407

14.1.10.3.1             Product launches and approvals         407

14.1.10.3.2             Deals      408

14.1.10.3.3             Expansions             409

14.1.11   DIASORIN S.P.A.                410

14.1.11.1                 Business overview 410

14.1.11.2                 Products offered   411

14.1.11.3                 Recent developments           413

14.1.11.3.1             Product launches and approvals         413

14.1.11.3.2             Deals      414

14.1.12   SIEMENS HEALTHINEERS AG      415

14.1.12.1                 Business overview 415

14.1.12.2                 Products offered   416

14.1.12.3                 Recent developments           417

14.1.12.3.1             Product launches and approvals         417

14.1.12.3.2             Deals      417

14.1.12.3.3             Expansions             418

14.1.13   BD          419

14.1.13.1                 Business overview 419

14.1.13.2                 Products offered   420

14.1.13.3                 Recent developments           421

14.1.13.3.1             Product launches and approvals         421

14.1.13.3.2             Deals      423

14.1.13.3.3             Expansions             423

14.2         OTHER PLAYERS              424

14.2.1      QUIDELORTHO CORPORATION                424

14.2.2      BRUKER                426

14.2.3      GENETIC SIGNATURES 428

14.2.4      CO-DIAGNOSTICS, INC. 429

14.2.5      VELA DIAGNOSTICS       430

14.2.6      MOLBIO DIAGNOSTICS PVT. LTD.           431

14.2.7      SAVYON DIAGNOSTICS 433

14.2.8      UNIOGEN OY     434

14.2.9      GENEOMBIO TECHNOLOGIES   435

14.2.10   ADVANCED MOLECULAR DIAGNOSTICS               436

14.2.11   ALTONA DIAGNOSTICS GMBH  438

14.2.12   GENEFIRST LIMITED      439

15            APPENDIX           440

15.1         DISCUSSION GUIDE        440

15.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                445

15.3         CUSTOMIZATION OPTIONS        447

15.4         RELATED REPORTS         447

15.5         AUTHOR DETAILS           448

LIST OF TABLES

TABLE 1                MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

INCLUSIONS AND EXCLUSIONS 40

TABLE 2                MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

KEY DATA FROM PRIMARY SOURCES     45

TABLE 3                MOLECULAR INFECTIOUS DISEASE TESTING MARKET: RISK ANALYSIS              55

TABLE 4                GLOBAL HIV DATA, 2020 VS. 2022 VS. 2023                 68

TABLE 5                INDICATIVE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, 2022–2024        73

TABLE 6                INDICATIVE SELLING PRICE TREND OF SEXUALLY TRANSMITTED DISEASE TESTS, BY KEY PLAYER, 2022–2024              73

TABLE 7                INDICATIVE SELLING PRICE TREND OF GASTROINTESTINAL INFECTIOUS DISEASE TESTS, BY KEY PLAYER, 2022–2024            74

TABLE 8                INDICATIVE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022–2024           74

TABLE 9                MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

ROLE OF COMPANIES IN ECOSYSTEM    78

TABLE 10              MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

INNOVATIONS AND PATENT REGISTRATIONS, 2022–2023                 83

TABLE 11              IMPORT DATA FOR HS CODE 3822 (DIAGNOSTIC AND LABORATORY REAGENTS), BY COUNTRY, 2019–2023 (USD MILLION)            84

TABLE 12              EXPORT DATA FOR HS CODE 3822 (DIAGNOSTIC AND LABORATORY REAGENTS), BY COUNTRY, 2019–2023 (USD MILLION)            85

TABLE 13              MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

KEY CONFERENCES AND EVENTS, 2025–2026        85

TABLE 14              CLASSIFICATION OF IVD DEVICES IN EUROPE                 89

TABLE 15              TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN         91

TABLE 16              CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA         92

TABLE 17              NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  94

TABLE 18              EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  94

TABLE 19              ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  94

TABLE 20              LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  95

TABLE 21              REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  95

TABLE 22              MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS       96

TABLE 23              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS,

BY PRODUCT & SERVICE (%)      98

TABLE 24              KEY BUYING CRITERIA, BY PRODUCT & SERVICE                 99

TABLE 25              MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        104

TABLE 26              KEY REAGENTS & KITS AVAILABLE IN MARKET                 105

TABLE 27              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS,

BY REGION, 2022–2029 (USD MILLION)   106

TABLE 28              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR REAGENTS & KITS, BY COUNTRY, 2022–2029 (USD MILLION)                 106

TABLE 29              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

REAGENTS & KITS, BY COUNTRY, 2022–2029 (USD MILLION)                 107

TABLE 30              ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2029 (USD MILLION)     107

TABLE 31              LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2029 (USD MILLION)     108

TABLE 32              KEY TESTING INSTRUMENTS AVAILABLE IN MARKET               109

TABLE 33              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS,

BY REGION, 2022–2029 (USD MILLION)   110

TABLE 34              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION)            110

TABLE 35              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION) 111

TABLE 36              ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION)            111

TABLE 37              LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION)            112

TABLE 38              KEY SOFTWARE SOLUTIONS AVAILABLE IN MARKET               113

TABLE 39              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SERVICES & SOFTWARE, BY REGION, 2022–2029 (USD MILLION)                 113

TABLE 40              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)     114

TABLE 41              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SERVICES & SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)            114

TABLE 42              ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SERVICES & SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)            114

TABLE 43              LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)     115

TABLE 44              MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            117

TABLE 45              KEY MULTIPLEX TESTING PRODUCTS AVAILABLE IN MARKET 118

TABLE 46              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING,

BY REGION, 2022–2029 (USD MILLION)   119

TABLE 47              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR MULTIPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)            119

TABLE 48              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

MULTIPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)                 120

TABLE 49              ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)     120

TABLE 50              LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)     121

TABLE 51              KEY SINGLEPLEX TESTING PRODUCTS AVAILABLE IN MARKET 122

TABLE 52              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY REGION, 2022–2029 (USD MILLION) 122

TABLE 53              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR SINGLEPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)            123

TABLE 54              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SINGLEPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)                 123

TABLE 55              ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)     123

TABLE 56              LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)     124

TABLE 57              MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)            126

TABLE 58              KEY LABORATORY-BASED TESTS AND DEVICES AVAILABLE IN MARKET 127

TABLE 59              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS,

BY REGION, 2022–2029 (USD MILLION)   128

TABLE 60              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)     128

TABLE 61              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)                 129

TABLE 62              ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)     129

TABLE 63              LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)     130

TABLE 64              KEY POINT OF CARE TESTS AND DEVICES AVAILABLE IN MARKET 131

TABLE 65              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT OF CARE TESTS, BY REGION, 2022–2029 (USD MILLION) 132

TABLE 66              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

POINT OF CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)                 132

TABLE 67              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

POINT OF CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)                 133

TABLE 68              ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

POINT OF CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)                 133

TABLE 69              LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

POINT OF CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)                 133

TABLE 70              MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE,

2022–2029 (USD MILLION)            135

TABLE 71              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)            136

TABLE 72              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)            137

TABLE 73              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         137

TABLE 74              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)               138

TABLE 75              ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         138

TABLE 76              LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         139

TABLE 77              KEY INFLUENZA TESTING PRODUCTS AVAILABLE IN MARKET 140

TABLE 78              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY REGION, 2022–2029 (USD MILLION)            140

TABLE 79              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR INFLUENZA, BY COUNTRY, 2022–2029 (USD MILLION)                 141

TABLE 80              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA,

BY COUNTRY, 2022–2029 (USD MILLION)               141

TABLE 81              ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2022–2029 (USD MILLION)            141

TABLE 82              LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR INFLUENZA, BY COUNTRY, 2022–2029 (USD MILLION)                 142

TABLE 83              KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE IN MARKET 143

TABLE 84              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS,

BY REGION, 2022–2029 (USD MILLION)   143

TABLE 85              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR TUBERCULOSIS, BY COUNTRY, 2022–2029 (USD MILLION)                 143

TABLE 86              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR TUBERCULOSIS, BY COUNTRY, 2022–2029 (IN THOUSANDS)                 144

TABLE 87              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022–2029 (USD MILLION)       144

TABLE 88              ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022–2029 (USD MILLION)            144

TABLE 89              LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022–2029 (USD MILLION)            145

TABLE 90              KEY PHARYNGITIS TESTING PRODUCTS AVAILABLE IN MARKET 146

TABLE 91              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS,

BY REGION, 2022–2029 (USD MILLION)   146

TABLE 92              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022–2029 (USD MILLION)            146

TABLE 93              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022–2029 (USD MILLION) 147

TABLE 94              ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022–2029 (USD MILLION)            147

TABLE 95              LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022–2029 (USD MILLION)            147

TABLE 96              OTHER KEY RESPIRATORY INFECTION DISEASE TESTING PRODUCTS

AVAILABLE IN MARKET 148

TABLE 97              MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)          149

TABLE 98              NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY,

2022–2029 (USD MILLION)            149

TABLE 99              EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         149

TABLE 100            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                 150

TABLE 101            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                 150

TABLE 102            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)                151

TABLE 103            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)          151

TABLE 104            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY,

2022–2029 (USD MILLION)            151

TABLE 105            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY,

2022–2029 (USD MILLION)            152

TABLE 106            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY,

2022–2029 (USD MILLION)            152

TABLE 107            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY,

2022–2029 (USD MILLION)            152

TABLE 108            KEY HEPATITIS TESTING PRODUCTS AVAILABLE IN MARKET 154

TABLE 109            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY REGION, 2022–2029 (USD MILLION)                 154

TABLE 110            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)       155

TABLE 111            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (IN THOUSANDS)  155

TABLE 112            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS,

BY COUNTRY, 2022–2029 (USD MILLION)               155

TABLE 113            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)       156

TABLE 114            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)       156

TABLE 115            OTHER KEY GASTROINTESTINAL INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET  157

TABLE 116            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION,

2022–2029 (USD MILLION)            157

TABLE 117            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                 158

TABLE 118            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY,

2022–2029 (USD MILLION)          158

TABLE 119            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY,

2022–2029 (USD MILLION)            158

TABLE 120            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY,

2022–2029 (USD MILLION)            159

TABLE 121            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            160

TABLE 122            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2022–2029 (USD MILLION)            160

TABLE 123            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         161

TABLE 124            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 161

TABLE 125            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 161

TABLE 126            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         162

TABLE 127            KEY HIV TESTING PRODUCTS AVAILABLE IN MARKET               163

TABLE 128            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY REGION,

2022–2029 (USD MILLION)            164

TABLE 129            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

HIV, BY COUNTRY, 2022–2029 (USD MILLION)     164

TABLE 130            NORTH AMERICA: MOLECULAR INFECTIOUS TESTING MARKET FOR HIV,

BY COUNTRY, 2022–2029 (IN THOUSANDS)           164

TABLE 131            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV,

BY COUNTRY, 2022–2029 (USD MILLION)               165

TABLE 132            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV,

BY COUNTRY, 2022–2029 (USD MILLION)               165

TABLE 133            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV,

BY COUNTRY, 2022–2029 (USD MILLION)               166

TABLE 134            KEY HUMAN PAPILLOMAVIRUS TESTING PRODUCTS AVAILABLE IN MARKET        167

TABLE 135            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

HUMAN PAPILLOMAVIRUS, BY REGION, 2022–2029 (USD MILLION)            167

TABLE 136            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022–2029 (USD MILLION)            168

TABLE 137            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022–2029 (USD MILLION)            168

TABLE 138            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022–2029 (USD MILLION)            168

TABLE 139            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022–2029 (USD MILLION)            169

TABLE 140            KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE IN MARKET        170

TABLE 141            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2022–2029 (USD MILLION)       170

TABLE 142            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022–2029 (USD MILLION)               170

TABLE 143            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022–2029 (USD MILLION)            171

TABLE 144            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022–2029 (USD MILLION)               171

TABLE 145            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022–2029 (USD MILLION)               171

TABLE 146            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2022–2029 (USD MILLION)       172

TABLE 147            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2022–2029 (USD MILLION)     173

TABLE 148            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

NEISSERIA GONORRHOEAE, BY COUNTRY, 2022–2029 (USD MILLION)            173

TABLE 149            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

NEISSERIA GONORRHOEAE, BY COUNTRY, 2022–2029 (USD MILLION)            173

TABLE 150            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2022–2029 (USD MILLION)     174

TABLE 151            KEY SYPHILIS TESTING PRODUCTS AVAILABLE IN MARKET         174

TABLE 152            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY REGION, 2022–2029 (USD MILLION)                 175

TABLE 153            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2022–2029 (USD MILLION)       175

TABLE 154            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS,

BY COUNTRY, 2022–2029 (USD MILLION)               176

TABLE 155            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SYPHILIS, BY COUNTRY, 2022–2029 (USD MILLION)          176

TABLE 156            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2022–2029 (USD MILLION)       177

TABLE 157            OTHER KEY SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS

AVAILABLE IN MARKET 178

TABLE 158            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER

SEXUALLY TRANSMITTED DISEASES, BY REGION, 2022–2029 (USD MILLION) 178

TABLE 159            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY,

2022–2029 (USD MILLION)            179

TABLE 160            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         179

TABLE 161            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            179

TABLE 162            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            180

TABLE 163            KEY HOSPITAL-ACQUIRED INFECTION TESTING PRODUCTS AVAILABLE IN MARKET     181

TABLE 164            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2022–2029 (USD MILLION)            181

TABLE 165            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022–2029 (USD MILLION)   182

TABLE 166            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022–2029 (USD MILLION)     182

TABLE 167            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022–2029 (USD MILLION)   182

TABLE 168            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022–2029 (USD MILLION)   183

TABLE 169            KEY VAGINITIS TESTING PRODUCTS AVAILABLE IN MARKET 184

TABLE 170            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY REGION, 2022–2029 (USD MILLION)                 184

TABLE 171            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2022–2029 (USD MILLION)       184

TABLE 172            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS,

BY COUNTRY, 2022–2029 (USD MILLION)               185

TABLE 173            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2022–2029 (USD MILLION)       185

TABLE 174            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2022–2029 (USD MILLION)       185

TABLE 175            KEY MENINGITIS TESTING PRODUCTS AVAILABLE IN MARKET 186

TABLE 176            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS,

BY REGION, 2022–2029 (USD MILLION)   187

TABLE 177            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022–2029 (USD MILLION)            187

TABLE 178            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022–2029 (USD MILLION) 187

TABLE 179            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022–2029 (USD MILLION)            188

TABLE 180            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022–2029 (USD MILLION)            188

TABLE 181            KEY VECTOR-BORNE DISEASE TESTING PRODUCTS AVAILABLE IN MARKET        189

TABLE 182            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY REGION, 2022–2029 (USD MILLION) 190

TABLE 183            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)     190

TABLE 184            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)     190

TABLE 185            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

VECTOR-BORNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            191

TABLE 186            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)     191

TABLE 187            OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET        192

TABLE 188            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)       192

TABLE 189            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)               193

TABLE 190            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            193

TABLE 191            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            193

TABLE 192            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            194

TABLE 193            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY,

2022–2029 (USD MILLION)            196

TABLE 194            KEY POLYMERASE CHAIN REACTION-BASED TESTS AND

DEVICES AVAILABLE IN MARKET              198

TABLE 195            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION)            199

TABLE 196            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)      199

TABLE 197            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)            200

TABLE 198            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)      200

TABLE 199            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)      201

TABLE 200            KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED

TESTS AND DEVICES AVAILABLE IN MARKET     202

TABLE 201            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2022–2029 (USD MILLION)   202

TABLE 202            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY,

2022–2029 (USD MILLION)            203

TABLE 203            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY,

2022–2029 (USD MILLION)            203

TABLE 204            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY,

2022–2029 (USD MILLION)            203

TABLE 205            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY,

2022–2029 (USD MILLION)            204

TABLE 206            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION)     205

TABLE 207            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY,

2022–2029 (USD MILLION)            205

TABLE 208            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY,

2022–2029 (USD MILLION)            206

TABLE 209            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY,

2022–2029 (USD MILLION)            206

TABLE 210            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY,

2022–2029 (USD MILLION)            207

TABLE 211            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN

SITU HYBRIDIZATION, BY REGION, 2022–2029 (USD MILLION)                 208

TABLE 212            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)     208

TABLE 213            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN

SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)                 209

TABLE 214            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)            209

TABLE 215            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN

SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)                 209

TABLE 216            KEY MICROARRAY-BASED PRODUCTS AVAILABLE IN MARKET 210

TABLE 217            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS,

BY REGION, 2022–2029 (USD MILLION)   211

TABLE 218            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

DNA MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)                 211

TABLE 219            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)            211

TABLE 220            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

DNA MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)                 212

TABLE 221            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

DNA MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)                 212

TABLE 222            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION) 213

TABLE 223            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)            213

TABLE 224            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)            214

TABLE 225            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)            214

TABLE 226            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)            214

TABLE 227            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)            216

TABLE 228            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)            217

TABLE 229            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)               218

TABLE 230            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)            218

TABLE 231            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)               218

TABLE 232            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)               219

TABLE 233            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)                 220

TABLE 234            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)     221

TABLE 235            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)                 221

TABLE 236            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)     221

TABLE 237            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)     222

TABLE 238            MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS,

BY REGION, 2022–2029 (USD MILLION)   222

TABLE 239            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)            223

TABLE 240            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)                 223

TABLE 241            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)                 223

TABLE 242            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)                 224

TABLE 243            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION,

2022–2029 (USD MILLION)            226

TABLE 244            MACROECONOMIC INDICATORS FOR NORTH AMERICA             228

TABLE 245            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               229

TABLE 246            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        229

TABLE 247            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         229

TABLE 248            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TEST TYPE, 2022–2029 (USD MILLION)             230

TABLE 249            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY DISEASE, 2022–2029 (USD MILLION)  230

TABLE 250            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   231

TABLE 251            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)                 231

TABLE 252            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)   232

TABLE 253            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     232

TABLE 254            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               233

TABLE 255            US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)            234

TABLE 256            US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            234

TABLE 257            US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)            235

TABLE 258            US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE,

2022–2029 (USD MILLION)            235

TABLE 259            US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)         236

TABLE 260            US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   236

TABLE 261            US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)                237

TABLE 262            US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     237

TABLE 263            US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)            238

TABLE 264            CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        239

TABLE 265            CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            239

TABLE 266            CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)                 239

TABLE 267            CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)                 240

TABLE 268            CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)         240

TABLE 269            CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   241

TABLE 270            CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            241

TABLE 271            CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)                 242

TABLE 272            CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)                 242

TABLE 273            MACROECONOMIC INDICATORS FOR EUROPE                 243

TABLE 274            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                 244

TABLE 275            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        244

TABLE 276            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            244

TABLE 277            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)                 245

TABLE 278            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)                 245

TABLE 279            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)            246

TABLE 280            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   246

TABLE 281            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            247

TABLE 282            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)                 247

TABLE 283            EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)                 248

TABLE 284            GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        249

TABLE 285            GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            250

TABLE 286            GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)                 250

TABLE 287            GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)                 250

TABLE 288            GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)         251

TABLE 289            GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   251

TABLE 290            GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            252

TABLE 291            GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     252

TABLE 292            GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)                 253

TABLE 293            UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        254

TABLE 294            UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            254

TABLE 295            UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)            255

TABLE 296            UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE,

2022–2029 (USD MILLION)            255

TABLE 297            UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)            256

TABLE 298            UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)       256

TABLE 299            UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)                257

TABLE 300            UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)                 257

TABLE 301            UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)            258

TABLE 302            FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        259

TABLE 303            FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            259

TABLE 304            FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)                 259

TABLE 305            FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)                 260

TABLE 306            FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)            260

TABLE 307            FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   261

TABLE 308            FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            261

TABLE 309            FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     262

TABLE 310            FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)                 262

TABLE 311            ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        263

TABLE 312            ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            264

TABLE 313            ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)            264

TABLE 314            ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE,

2022–2029 (USD MILLION)            264

TABLE 315            ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)            265

TABLE 316            ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   265

TABLE 317            ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            266

TABLE 318            ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)                 266

TABLE 319            ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)            267

TABLE 320            RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        268

TABLE 321            RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            268

TABLE 322            RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)                 268

TABLE 323            RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE,

2022–2029 (USD MILLION)            269

TABLE 324            RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)            269

TABLE 325            RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   270

TABLE 326            RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            270

TABLE 327            RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)                 271

TABLE 328            RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)                 271

TABLE 329            SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        272

TABLE 330            SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            273

TABLE 331            SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)                 273

TABLE 332            SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE,

2022–2029 (USD MILLION)            274

TABLE 333            SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)            274

TABLE 334            SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   275

TABLE 335            SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            275

TABLE 336            SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)                 276

TABLE 337            SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)                 276

TABLE 338            REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        277

TABLE 339            REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         277

TABLE 340            REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TEST TYPE, 2022–2029 (USD MILLION)             278

TABLE 341            REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY DISEASE, 2022–2029 (USD MILLION)  278

TABLE 342            REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   279

TABLE 343            REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)                 279

TABLE 344            REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)   280

TABLE 345            REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     280

TABLE 346            REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               281

TABLE 347            MACROECONOMIC INDICATORS FOR ASIA PACIFIC                283

TABLE 348            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)            283

TABLE 349            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION) 283

TABLE 350            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)                 284

TABLE 351            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)            284

TABLE 352            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY DISEASE, 2022–2029 (USD MILLION)  285

TABLE 353            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   285

TABLE 354            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)                 286

TABLE 355            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            286

TABLE 356            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     287

TABLE 357            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               287

TABLE 358            CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        289

TABLE 359            CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            289

TABLE 360            CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)                 289

TABLE 361            CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE,

2022–2029 (USD MILLION)            290

TABLE 362            CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)            290

TABLE 363            CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   291

TABLE 364            CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            291

TABLE 365            CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)                 292

TABLE 366            CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)                 292

TABLE 367            JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)            294

TABLE 368            JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            294

TABLE 369            JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)                 294

TABLE 370            JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE,

2022–2029 (USD MILLION)            295

TABLE 371            JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)         295

TABLE 372            JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   296

TABLE 373            JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            296

TABLE 374            JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)                 297

TABLE 375            JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)                 297

TABLE 376            INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        298

TABLE 377            INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            299

TABLE 378            INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)            299

TABLE 379            INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE,

2022–2029 (USD MILLION)            300

TABLE 380            INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)            300

TABLE 381            INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   301

TABLE 382            INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            301

TABLE 383            INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)                 302

TABLE 384            INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)            302

TABLE 385            AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        304

TABLE 386            AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            304

TABLE 387            AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)                 304

TABLE 388            AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)                 305

TABLE 389            AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)         305

TABLE 390            AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   306

TABLE 391            AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            306

TABLE 392            AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     307

TABLE 393            AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               307

TABLE 394            REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        308

TABLE 395            REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         309

TABLE 396            REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TEST TYPE, 2022–2029 (USD MILLION)             309

TABLE 397            REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY DISEASE, 2022–2029 (USD MILLION)  310

TABLE 398            REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION) 310

TABLE 399            REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)       311

TABLE 400            REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION) 311

TABLE 401            REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     312

TABLE 402            REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               312

TABLE 403            MACROECONOMIC INDICATORS FOR LATIN AMERICA             313

TABLE 404            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               314

TABLE 405            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        314

TABLE 406            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         314

TABLE 407            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TEST TYPE, 2022–2029 (USD MILLION)             315

TABLE 408            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY DISEASE, 2022–2029 (USD MILLION)  315

TABLE 409            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   316

TABLE 410            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)                 316

TABLE 411            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)   317

TABLE 412            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     317

TABLE 413            LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               318

TABLE 414            BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        319

TABLE 415            BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            319

TABLE 416            BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)                 320

TABLE 417            BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE,

2022–2029 (USD MILLION)            320

TABLE 418            BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)         321

TABLE 419            BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   321

TABLE 420            BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            322

TABLE 421            BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)                 322

TABLE 422            BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)                 323

TABLE 423            MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        324

TABLE 424            MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2022–2029 (USD MILLION)            324

TABLE 425            MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)                 324

TABLE 426            MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)                 325

TABLE 427            MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)            325

TABLE 428            MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   326

TABLE 429            MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR

SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)            326

TABLE 430            MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)                 327

TABLE 431            MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)                 327

TABLE 432            REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        328

TABLE 433            REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         329

TABLE 434            REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TEST TYPE, 2022–2029 (USD MILLION)             329

TABLE 435            REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY DISEASE, 2022–2029 (USD MILLION)  329

TABLE 436            REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)                 330

TABLE 437            REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE,

2022–2029 (USD MILLION)            330

TABLE 438            REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)                 330

TABLE 439            REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     331

TABLE 440            REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               331

TABLE 441            MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        333

TABLE 442            MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         333

TABLE 443            MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TEST TYPE, 2022–2029 (USD MILLION)             333

TABLE 444            MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY DISEASE, 2022–2029 (USD MILLION)  334

TABLE 445            MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION) 334

TABLE 446            MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)       335

TABLE 447            MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET

FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION) 335

TABLE 448            MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     336

TABLE 449            MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               336

TABLE 450            MACROECONOMIC INDICATORS FOR MIDDLE EAST & AFRICA 337

TABLE 451            GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)        338

TABLE 452            GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         338

TABLE 453            GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TEST TYPE, 2022–2029 (USD MILLION)             338

TABLE 454            GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY DISEASE, 2022–2029 (USD MILLION)  339

TABLE 455            GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)   339

TABLE 456            GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)                 339

TABLE 457            GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)   340

TABLE 458            GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY TECHNOLOGY, 2022–2029 (USD MILLION)     340

TABLE 459            GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               341

TABLE 460            MACROECONOMIC INDICATORS FOR GCC COUNTRIES        341

TABLE 461            OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, JANUARY 2021–DECEMBER 2024             342

TABLE 462            MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DEGREE OF COMPETITION    346

TABLE 463            MOLECULAR INFECTIOUS DISEASE TESTING MARKET: REGION FOOTPRINT 352

TABLE 464            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

PRODUCT & SERVICE FOOTPRINT           353

TABLE 465            MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TEST TYPE FOOTPRINT            354

TABLE 466            MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DISEASE FOOTPRINT 355

TABLE 467            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

DETAILED LIST OF KEY STARTUPS/SMES             358

TABLE 468            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)                 358

TABLE 469            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)                 359

TABLE 470            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024                360

TABLE 471            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

DEALS, JANUARY 2021–DECEMBER 2024 361

TABLE 472            DANAHER: COMPANY OVERVIEW            362

TABLE 473            DANAHER: PRODUCTS OFFERED             363

TABLE 474            DANAHER: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–DECEMBER 2024 365

TABLE 475            DANAHER: DEALS, JANUARY 2021–DECEMBER 2024        366

TABLE 476            DANAHER: EXPANSIONS, JANUARY 2021–DECEMBER 2024                366

TABLE 477            F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW          368

TABLE 478            F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED             369

TABLE 479            F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–DECEMBER 2024 371

TABLE 480            F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021–DECEMBER 2024 372

TABLE 481            F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2021–DECEMBER 2024 373

TABLE 482            BIOMÉRIEUX: COMPANY OVERVIEW      374

TABLE 483            BIOMÉRIEUX: PRODUCTS OFFERED       375

TABLE 484            BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–DECEMBER 2024 377

TABLE 485            BIOMÉRIEUX: DEALS, JANUARY 2021–DECEMBER 2024                378

TABLE 486            HOLOGIC, INC.: COMPANY OVERVIEW  380

TABLE 487            HOLOGIC, INC.: PRODUCTS OFFERED   381

TABLE 488            HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–DECEMBER 2024 382

TABLE 489            HOLOGIC, INC.: DEALS, JANUARY 2021–DECEMBER 2024                383

TABLE 490            ABBOTT: COMPANY OVERVIEW                385

TABLE 491            ABBOTT: PRODUCTS OFFERED 386

TABLE 492            ABBOTT: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–DECEMBER 2024 388

TABLE 493            ABBOTT: DEALS, JANUARY 2021–DECEMBER 2024        388

TABLE 494            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          390

TABLE 495            THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED             391

TABLE 496            THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024                 392

TABLE 497            THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–DECEMBER 2024 393

TABLE 498            QIAGEN: COMPANY OVERVIEW 394

TABLE 499            QIAGEN: PRODUCTS OFFERED 395

TABLE 500            QIAGEN: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–DECEMBER 2024 396

TABLE 501            QIAGEN: DEALS, JANUARY 2021–DECEMBER 2024        398

TABLE 502            QIAGEN: EXPANSIONS, JANUARY 2021–DECEMBER 2024                398

TABLE 503            REVVITY: COMPANY OVERVIEW               399

TABLE 504            REVVITY: PRODUCTS OFFERED                401

TABLE 505            GRIFOLS, S.A.: COMPANY OVERVIEW      402

TABLE 506            GRIFOLS, S.A.: PRODUCTS OFFERED       403

TABLE 507            GRIFOLS, S.A.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–DECEMBER 2024 404

TABLE 508            GRIFOLS, S.A.: DEALS, JANUARY 2021–DECEMBER 2024                404

TABLE 509            SEEGENE INC.: COMPANY OVERVIEW    405

TABLE 510            SEEGENE INC.: PRODUCTS OFFERED     406

TABLE 511            SEEGENE INC.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–DECEMBER 2024 407

TABLE 512            SEEGENE INC.: DEALS, JANUARY 2021–DECEMBER 2024                408

TABLE 513            SEEGENE INC.: EXPANSIONS, JANUARY 2021–DECEMBER 2024                409

TABLE 514            DIASORIN S.P.A.: COMPANY OVERVIEW 410

TABLE 515            DIASORIN S.P.A.: PRODUCTS OFFERED 411

TABLE 516            DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–DECEMBER 2024 413

TABLE 517            DIASORIN S.P.A.: DEALS, JANUARY 2021–DECEMBER 2024                414

TABLE 518            SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW          415

TABLE 519            SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED             416

TABLE 520            SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–DECEMBER 2024 417

TABLE 521            SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–DECEMBER 2024     417

TABLE 522            SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021–DECEMBER 2024 418

TABLE 523            BD: COMPANY OVERVIEW           419

TABLE 524            BD: PRODUCTS OFFERED            420

TABLE 525            BD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024 421

TABLE 526            BD: DEALS, JANUARY 2021–DECEMBER 2024                 423

TABLE 527            BD: EXPANSIONS, JANUARY 2021–DECEMBER 2024        423

TABLE 528            QUIDELORTHO CORPORATION: COMPANY OVERVIEW          424

TABLE 529            BRUKER: COMPANY OVERVIEW 426

TABLE 530            GENETIC SIGNATURES: COMPANY OVERVIEW                 428

TABLE 531            CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW                 429

TABLE 532            VELA DIAGNOSTICS: COMPANY OVERVIEW                 430

TABLE 533            MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW          431

TABLE 534            SAVYON DIAGNOSTICS: COMPANY OVERVIEW                 433

TABLE 535            UNIOGEN OY: COMPANY OVERVIEW      434

TABLE 536            GENEOMBIO TECHNOLOGIES: COMPANY OVERVIEW          435

TABLE 537            ADVANCED MOLECULAR DIAGNOSTICS: COMPANY OVERVIEW   436

TABLE 538            ALTONA DIAGNOSTICS: COMPANY OVERVIEW                 438

TABLE 539            GENEFIRST LIMITED: COMPANY OVERVIEW                 439

LIST OF FIGURES

FIGURE 1              MOLECULAR INFECTIOUS DISEASE TESTING MARKET SEGMENTATION

AND REGIONS COVERED              39

FIGURE 2              MOLECULAR INFECTIOUS DISEASE TESTING MARKET: RESEARCH DESIGN     42

FIGURE 3              KEY INDUSTRY INSIGHTS             47

FIGURE 4              BREAKDOWN OF PRIMARY INTERVIEWS:

SUPPLY- AND DEMAND-SIDE PARTICIPANTS     47

FIGURE 5              BREAKDOWN OF PRIMARY INTERVIEWS:

BY COMPANY TYPE, DESIGNATION, AND REGION            48

FIGURE 6              BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH              49

FIGURE 7              CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 51

FIGURE 8              MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TOP-DOWN APPROACH            52

FIGURE 9              MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DATA TRIANGULATION            53

FIGURE 10            MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PARAMETRIC ASSUMPTIONS 54

FIGURE 11            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)                 56

FIGURE 12            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE,

2024 VS. 2029 (USD MILLION)      57

FIGURE 13            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE,

2024 VS. 2029 (USD MILLION)      57

FIGURE 14            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE,

2024 VS. 2029 (USD MILLION)      58

FIGURE 15            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY,

2024 VS. 2029 (USD MILLION)      59

FIGURE 16            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER,

2024 VS. 2029 (USD MILLION)      60

FIGURE 17            MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION,

2024 VS. 2029 (USD MILLION)      60

FIGURE 18            RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET         62

FIGURE 19            REAGENTS & KITS SEGMENT TO DOMINATE MARKET IN 2029                62

FIGURE 20            MULTIPLEX TESTING SEGMENT TO HAVE LARGEST MARKET SHARE IN 2029             63

FIGURE 21            LABORATORY TESTS TO HOLD LARGEST MARKET SHARE IN 2029 63

FIGURE 22            SEXUALLY TRANSMITTED DISEASES SEGMENT TO LEAD MARKET IN 2029            64

FIGURE 23            POLYMERASE CHAIN REACTION SEGMENT TO HAVE LARGEST MARKET

SHARE IN 2029   64

FIGURE 24            DIAGNOSTIC LABORATORIES SEGMENT TO COMMAND LARGEST MARKET

SHARE IN 2029   65

FIGURE 25            ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD           65

FIGURE 26            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES                 66

FIGURE 27            NEW REVENUE POCKETS FOR PLAYERS IN

MOLECULAR INFECTIOUS DISEASE TESTING MARKET  72

FIGURE 28            MOLECULAR INFECTIOUS DISEASE TESTING MARKET: VALUE CHAIN ANALYSIS           76

FIGURE 29            MOLECULAR INFECTIOUS DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS         77

FIGURE 30            MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ECOSYSTEM ANALYSIS              78

FIGURE 31            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

INVESTMENT AND FUNDING SCENARIO, 2021–2024          79

FIGURE 32            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

PATENT ANALYSIS, JANUARY 2014–DECEMBER 2023         82

FIGURE 33            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

PORTER’S FIVE FORCES ANALYSIS           96

FIGURE 34            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE         98

FIGURE 35            KEY BUYING CRITERIA, BY PRODUCT & SERVICE                 99

FIGURE 36            MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE

TESTING APPLICATIONS              100

FIGURE 37            REGIONAL INCIDENCE OF HIV, 2023        163

FIGURE 38            NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT 228

FIGURE 39            ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT 282

FIGURE 40            REVENUE ANALYSIS OF KEY PLAYERS IN MOLECULAR INFECTIOUS

DISEASE TESTING MARKET, 2021–2023    345

FIGURE 41            MARKET SHARE ANALYSIS OF KEY PLAYERS IN MOLECULAR INFECTIOUS

DISEASE TESTING MARKET, 2023               345

FIGURE 42            MARKET SHARE ANALYSIS OF KEY PLAYERS IN EMEA REGION IN

MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023                 347

FIGURE 43            EV/EBITDA OF KEY VENDORS, 2024         347

FIGURE 44            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF

KEY VENDORS, 2024        348

FIGURE 45            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

BRAND/PRODUCT COMPARISON             348

FIGURE 46            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023  350

FIGURE 47            MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY FOOTPRINT             351

FIGURE 48            MOLECULAR INFECTIOUS DISEASE TESTING MARKET:

COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023                 357

FIGURE 49            DANAHER: COMPANY SNAPSHOT (2023)                 363

FIGURE 50            F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)             369

FIGURE 51            BIOMÉRIEUX: COMPANY SNAPSHOT (2023)                 375

FIGURE 52            HOLOGIC, INC.: COMPANY SNAPSHOT (2024)                 381

FIGURE 53            ABBOTT: COMPANY SNAPSHOT (2023)  386

FIGURE 54            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)             391

FIGURE 55            QIAGEN: COMPANY SNAPSHOT (2023)   395

FIGURE 56            REVVITY: COMPANY SNAPSHOT (2023)  400

FIGURE 57            GRIFOLS, S.A.: COMPANY SNAPSHOT (2023)                 403

FIGURE 58            SEEGENE INC.: COMPANY SNAPSHOT (2023)                 406

FIGURE 59            DIASORIN S.P.A.: COMPANY SNAPSHOT (2023)                 411

FIGURE 60            SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)             416

FIGURE 61            BD: COMPANY SNAPSHOT (2024)              420

MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • ご注文後2営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

割引可能なレポートが多数ございます。価格・サンプルについてはお気軽にご相談ください。

最新調査レポート

• 沈降シリカ市場 – 2030年までの世界予測 2025-03-07
• スマートメーター市場 – 2030年までの世界予測 2025-03-07
• 産業用計測市場 – 2030年までの世界予測 2025-03-06
• 精密ろ過膜市場- 2029年までの世界予測 2025-03-06
• グリーンテクノロジーと持続可能性市場 – 2030年までの世界予測 2025-03-06

MarketsandMarkets  出版レポート一覧